viewRedx Pharma PLC

Redx Pharma hails new fibrosis drug candidate

RXC006 is a new breed of pill called a porcupine inhibitor

Idiopathic pulmonary fibrosis is a rare, but life-threatening lung disease

Redx Pharma Plc (LON:REDX) has unveiled a new drug candidate, which will enter clinical trials in 2020.

RXC006 is a new breed of pill called a porcupine inhibitor and it will be used as a first-in-class treatment for a rare but life-threatening disease called idiopathic pulmonary fibrosis.

READ: Redx Pharma poster assesses the direct tumour targeting of cancer candidate

Known as IPF for short, it is a chronic lung condition with a very poor prognosis and limited medication options.

Developing a drug for a small patient group where there is no drug specifically designed to treat the ailment can often speed up the long process of gaining regulatory approval. It should be stressed, Redx hasn’t discussed this aspect in the latest update.

It did, however, say, RXC006 has performed well in pre-clinical studies. Redx said it had been “potent and highly effective at suppressing the Wnt pathway”.

The Wnt pathway essentially helps regulate gene transcription, cell shape and the amount of calcium in the cell.

Redx has shown the involvement of the Wnt pathway increases with disease severity in IPF.

It is hoped RXC006 can offer patients with a severe form of the disease a drug option where there is currently no effective therapy beyond palliative care.

“IPF is a devastating disease with little effective treatment and there is, therefore, a clear unmet need for new therapies,” said chief executive Lisa Anson.

“Redx is excited to bring its precision medicinal chemistry expertise to bear with the discovery of this novel drug candidate. We look forward to taking RXC006 into clinical development; we plan to enter first in man clinical trials during 2020, in line with our strategy."

Quick facts: Redx Pharma PLC

Price: 55 GBX

Market: AIM
Market Cap: £107.39 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma PLC named herein, including the promotion by the Company of Redx Pharma PLC in any Content on the Site, the Company receives from...



Redx Pharma PLC in a great place to move forward after Astra deal says CEO

Lisa Anson, chief executive of Redx Pharma PLC (LON:REDX) says the out-license deal with AstraZeneca for its fibrosis porcupine inhibitor is good news for the company and also for people suffering from the condition. Using a porcupine inhibitor in lung-scarring diseases such as IPF is a novel...

1 day, 9 hours ago

2 min read